(NP (NP (NNS Eicosanoids)) (PP (IN in) (NP (NN breast) (NN cancer) (NNS patients))) (PP-TMP (PP-COOD (PP (IN before) (NP (-NONE- *RNR*-36))) (CC and) (PP (IN after) (NP (-NONE- *RNR*-36)))) (NP-36 (NN mastectomy))) (. .))
(S (PP (IN In) (NP (NP (CD 19) (NNS patients)) (PP (IN with) (NP (DT a) (JJ malignant) (NN breast) (NN tumor))))) (, ,) (NP-SBJ-COOD-301 (NP (NN tumor) (NN tissue)) (CC and) (NP (NN blood))) (VP (VBD were) (VP (VBN taken) (NP (-NONE- *-301)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB determine) (NP (DT the) (NP-COOD (NP (NN eicosanoid) (NN profile)) (CC and) (NP (NN platelet) (NN aggregation))))))))) (. .))
(S (NP-SBJ-37 (NNS Values)) (VP (VBD were) (VP (VBN compared) (NP (-NONE- *-37)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (NNS patients)) (UCP-COOD (PP (IN with) (NP (NP (JJ benign) (NNS tumors)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN n)) (VP (JJ =) (NP (CD 4)))) (-RRB- -RRB-)))) (, ,) (CC or) (VP (VBG undergoing) (NP (NP (DT a) (JJ mammary) (NN reduction)) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN n)) (VP (JJ =) (NP (CD 7)))) (-RRB- -RRB-))))))))))) (. .))
(S (ADVP-TMP (RB Postoperatively)) (, ,) (NP-SBJ-38 (NN blood)) (VP (VBD was) (VP (VBN taken) (NP (-NONE- *-38)) (PP (RB as) (ADVP (RB well))) (SBAR (IN in) (NN order) (TO to) (S (NP-SBJ (-NONE- *)) (VP (VB compare) (NP (ADJP-COOD (ADJP (JJ pre-) (ADJP (-NONE- *?*))) (CC and) (ADJP (JJ postoperative))) (NNS values))))))) (. .))
(S (S (NP-SBJ-39 (NNS Eicosanoids)) (VP (VBD were) (VP (VBN measured) (NP (-NONE- *-39)) (PP (IN in) (NP-COOD (NP (JJ peripheral) (NN blood) (NNS monocytes)) (CC and) (NP (JJ mammary) (NN tissue)))) (PP (IN by) (NNS means) (IN of) (NP (NN HPLC))))) (: ;)) (S (ADVP (RBR furthermore)) (, ,) (NP-SBJ-COOD-40 (NP (NN TXA2)) (, ,) (NP (NN 6-keto-PGF1) (NN alpha)) (, ,) (CC and) (NP (NN PGE2))) (VP (VBD were) (VP (VBN determined) (NP (-NONE- *-40)) (PP (IN by) (NP-LGS (NN RIA))))) (. .)))
(S (S (NP-SBJ-41 (NP (NNS Differences)) (PP (IN in) (NP (NP (ADJP-COOD (ADJP (JJ pre-) (ADJP (-NONE- *?*))) (CC and) (ADJP (JJ postoperative))) (NNS values)) (PP (IN of) (NP (NN cancer) (NNS patients)))))) (VP (VBD were) (VP (VBN seen) (NP (-NONE- *-41)) (PP (IN in) (NP (NN plasma) (NN RIA) (NNS values))))) (: :)) (S-COOD (S (NP-SBJ-COOD-302 (NP (NN PGE2)) (CC and) (NP (NN 6-k-PGF1) (NN alpha))) (VP (VBD were) (ADJP-PRD (RB significantly) (JJR higher)) (ADVP-TMP (RB preoperatively)) (SBAR-TMP (WHADVP-42 (WRB when)) (S (NP-SBJ-303 (-NONE- *-302)) (VP (VBN compared) (NP (-NONE- *-303)) (PP (IN with) (FRAG (ADVP (RB postoperatively)))) (ADVP (-NONE- *T*-42))))))) (, ,) (RB however) (, ,) (S (NP-SBJ-43 (JJ such) (NNS differences)) (VP (VBD were) (VP (VBN seen) (NP (-NONE- *-43)) (PP (IN in) (NP (DT the) (NN control) (NNS groups))) (PP (RB as) (ADVP (RB well))))))) (. .))
(S (PP (VBN Compared) (PP (TO to) (NP (NP-COOD (NP (JJ benign) (NN tumor)) (CC or) (NP (JJ mammary) (NN reduction))) (NN test) (NN material)))) (NP-SBJ-44 (NP (DT the) (NN eicosanoid) (NN profile)) (PP (IN of) (NP (NP (NN tissue)) (VP (VBN obtained) (NP (-NONE- *)) (PP (IN from) (NP (JJ malignant) (JJ mammary) (NNS tumors))))))) (VP (VBD showed) (NP (JJ important) (NNS differences))) (. .))
(S-COOD (S (PP (IN Except) (IN for) (NP-COOD (NP (NN PGF2) (NN alpha)) (, ,) (NP (NN HHT)) (CC and) (NP (NN 15-HETE)))) (NP-SBJ-46 (NP (DT no) (JJ detectable) (NNS quantities)) (PP (IN of) (NP (NNS eicosanoids)))) (VP (VBD were) (VP (VBN found) (NP (-NONE- *-46)) (PP (IN in) (NP (DT the) (JJ non-tumor) (NN material)))))) (, ,) (IN whereas) (S (PP (IN in) (NP (DT the) (JJ malignant) (NN tumor) (NN material))) (NP-SBJ (NP (JJ substantial) (NNS quantities)) (PP (IN of) (NP (NP (DT a) (NN number)) (PP (IN of) (NP (NN eicosanoid) (NNS metabolites)))))) (VP (VBD were) (ADJP-PRD (JJ present)))) (. .))
(S (NP-SBJ-47 (ADJP (RB Statistically) (JJ significant)) (NNS correlations)) (VP (MD could) (VP (VB be) (VP (VBN established) (NP (-NONE- *-47)) (PP (PP (IN between) (NP-COOD (NP (NN (histopathology patient)) (NNS data)) (CC and) (NP (NP (DT the) (NNS results)) (PP (IN of) (NP (DT the) (NN platelet) (NN aggregation) (NNS assays)))))) (, ,) (FW e.g.) (PP (IN between) (NP-COOD (NP-COOD (NP (JJ menopausal) (NN status)) (CC and) (NP (NN ADP) (NN aggregation))) (: ;) (NP-COOD (NP (NN oestrogen) (NN receptor) (PRN (-LRB- -LRB-) (NP (JJ (- +))) (-RRB- -RRB-))) (CC and) (NP (NN collagen)) (CC and) (NP (JJ arachidonic) (NN acid) (NN aggregation))) (, ,) (NP-COOD (NP (JJ inflammatory) (NN cell) (NN infiltration) (NN score)) (CC and) (NP (JJ arachidonic) (NN acid) (NN aggregation))) (CC and) (NP-COOD (NP (NN fibrosis) (NN score)) (CC and) (NP (NN ADP) (NN aggregation))))))))) (. .))
(S (NP-SBJ (DT The) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NP (NN eicosanoid) (NN synthesis)) (PP (IN in) (NP (NP (NN material)) (PP (IN from) (NP (JJ mammary) (NN cancer) (NNS patients)))))) (VP (VBZ is) (ADJP-PRD (JJ different) (PP (IN from) (NP (NP (DT that)) (PP (IN in) (NP (JJ benign) (JJ mammary) (NN tissue)))))))))) (. .))
(S (NP-SBJ (NP (DT The) (NNS implications)) (PP (, ,) (PP (IN in) (NP (JJ particular))) (, ,) (IN in) (NN relation) (TO to) (NP (NP (JJ future) (NN prognosis)) (PP (IN of) (NP (DT the) (NN patient)))) (, ,))) (VP (VBP remain) (ADJP-PRD (JJ obscure))) (. .))
